By indication / Other radioligand therapy
Other radioligand therapy
4 imaging agents and 22 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [18F]FBPA | F-18 | Preclinical | 6 |
| [99mTc]Tc-PSMA-I&S | Tc-99m | — | 4 |
| [89Zr]Zr-DFO-girentuximab | Zr-89 | Clinical research | 1 |
| [18F]fluorophenylalanine | F-18 | Clinical research |
Therapy
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [225Ac]Ac-DOTA-YS5 | Ac-225 | Preclinical | 4 |
| [177Lu]Lu-pentixather paired with [68Ga]Ga-Pentixafor | Lu-177 | Clinical research | 3 |
| [177Lu]Lu-PP-F11N | Lu-177 | Clinical research | 3 |
| [225Ac]Ac-Macropa-PEG4-YS5 | Ac-225 | — | 3 |
| [131I]MIBG paired with [123I]MIBG | I-131 | Approved | 2 |
| [177Lu]Lu-AKIR001 | Lu-177 | Clinical research | 2 |
| [177Lu]Lu-DOTA-DV1-K-DV3 | Lu-177 | Preclinical | 2 |
| [225Ac]Ac-DOTA-CCK-66 paired with [68Ga]Ga-DOTA-CCK-66 | Ac-225 | Preclinical | 1 |
| [225Ac]Ac-DOTAZOL | Ac-225 | Preclinical | 1 |
| [131I]I-131-PD-L1 | I-131 | — | 1 |
| [90Y]Y-90-FF-21101 | Y-90 | Clinical research | 1 |
| [161Tb]Tb-BL02 | Tb-161 | Preclinical | 1 |
| [225Ac]Ac-mcp-TDI-Y-010 | Ac-225 | Reported once | 1 |
| [177Lu]Lu-DOTA-GA13 | Lu-177 | Reported once | 1 |
| [161Tb]Tb-cAC10 | Tb-161 | Reported once | 1 |
| [225Ac]Ac(MacropaSq-hG250) | Ac-225 | Preclinical | 1 |
| [177Lu]Lu-DTPA-NY003 | Lu-177 | Preclinical | 1 |
| [90Y]Y-pentixather | Y-90 | — | |
| [211At]At-211-AMT paired with [11C]AMT | At-211 | Preclinical | |
| [177Lu]Lu-CE-21 paired with [68Ga]CE-21 | Lu-177 | Clinical research | |
| [212Pb]Pb-DO3A-PEG7-Tz | Pb-212 | Preclinical | |
| 2-[211At]astato-α-methyl-L-phenylalanine | At-211 | Preclinical |
Other entries
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [111In]In-minigastrin | In-111 | — | 2 |
| [177Lu]Lu-DOTA-A1K2 | Lu-177 | Preclinical | 1 |
| [177Lu]Lu-DOTA-M5A | Lu-177 | Preclinical | 1 |
| [90Y]Y-DOTA-AR | Y-90 | Preclinical | 1 |
| [188Re]Re-Tin colloid | Re-188 | — | 1 |
| [166Ho]Ho-DTPA | Ho-166 | Preclinical | |
| [161Tb]Tb-DOTA-IBA | Tb-161 | Clinical research | |
| [213Bi]Bi-B-B4 | Bi-213 | Preclinical | |
| [211At]At-(RGD)4 | At-211 | Preclinical | |
| [177Lu]Lu-hydroxyapatite | Lu-177 | Preclinical | |
| [166Ho]Ho-labeled microspheres | Ho-166 | Preclinical | |
| [153Sm]Sm-HA | Sm-153 | Approved | |
| [211At]At-antiCD33 | At-211 | Preclinical | |
| [188Re]Re-6D2 | Re-188 | Clinical research | |
| [212Pb]Pb-DOTA-Re(Arg11)CCMSH | Pb-212 | Preclinical |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region - tell us what you need.
Get in touch